Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Tenofovir Amibufenamide on Blood Lipids in Chronic Hepatitis B
NCT05398393Unknown
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Open-label trial of tenofovir + amibufenamide in hepatitis B (HBV) (3 arms). Primary endpoints: change from baseline HBV-DNA at 12 months and change from baseline level of blood lipid at 12 months. Status: unknown.
02
Drugs
tenofovir + amibufenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05398393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398393.